跳至主要内容
临床试验/EUCTR2012-003589-42-DE
EUCTR2012-003589-42-DE进行中(未招募)不适用

Observational (non-interventional), follow-up trial assessing long-term local tolerability and efficacy (recurrence rate) of resiquimod gel in patients treated for actinic keratosis.

Spirig Pharma AG0 个研究点目标入组 80 人开始时间: 2012年12月19日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Signed informed consent.
  • Participation in the previous clinical trial SP848-AK-1101.
  • Patient with complete clinical clearance (i.e. no previously existing AK-lesion present) at the end of the trial SP848-AK-1101 or Non-Responder who withdrew from the trial prematurely.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 30
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 50

排除标准

  • Evidence of unstable or uncontrolled clinically significant medical conditions as determined by the investigator (e.g., cardiovascular, immunological, hematologic, hepatic, neurologic, renal, endocrine, collagen-vascular, infectious, gastrointestinal abnormalities or diseases).
  • Evidence of systemic cancer.
  • Dermatological disease or condition in the former treatment or surrounding area that might
  • impair trial assessments (e.g., rosacea, atopic dermatitis, eczema) as assessed by the investigator.

研究者

相似试验

Observational (non-interventional), follow-up trial... | 临床试验